Robotics has become one of the fastest-growing sectors globally. According to ABI Research, the global robotics market is expected to be valued at nearly $50 billion in 2025, an 11% increase over 2024. Meanwhile, the advanced robotics segment, which includes smart, adaptive systems is projected to reach $53.74 billion in 2025, growing rapidly to $280 billion by 2034.
Yet for all this growth, the core reason we build robots hasn’t changed: to take on tasks that humans aren’t optimized for, whether hazardous, repetitive or simply low-value relative to human cognitive potential.
Consider extreme environments: Mars, deep oceans or dangerous biocontainment zones. Robots in those settings are safer, more productive, and more cost-efficient. In biotech, though, the case is more subtle. The challenge is not brute scale, but flexibility, safety and augmentation of human skills.
Why Robots in Research Are Not “Job Killers”
A common myth, even in biotech, is that ‘robots take jobs’. That’s not how the best research labs see them. Robots in labs aren’t built to replace scientists. They are built to reclaim time for scientists, letting them defer rote protocol steps to machines and spend effort on insight, iteration and discovery.
Replacing humans purely for cost often backfires, because robotics engineering, integration, and maintenance bring complexity and overhead. From where I sit, the true value of robots is not substitution. It’s an amplification of human potential.
Research vs. Manufacturing — Why the Gap Persists
The biggest tension in biotech originates in this contrast: manufacturing thrives on repetition; research demands adaptation.
On a factory line, you can optimize one task, then repeat it millions of times. That works beautifully with industrial robotics. In a lab, the next experiment often differs — pipette volumes change, protocols shift, plates vary, reagents evolve. The “same task over and over” model rarely applies.
However, that does not mean robots have no place in research. They bring two essential advantages:
- Safety, reducing human exposure to radiation, solvents, pathogens and hazardous conditions.
- Labor reallocation, relieving highly trained scientists from repetitive tasks so they can focus on analysis, design, planning and problem-solving.
The hardware is already ahead in many respects. A $10,000 robotic arm can reliably position itself with sub-100-micron accuracy, well beyond human steadiness. The bottleneck is not mechanical. It’s control, programmability and adaptability.
Many labs still require hours of manual reprogramming to adjust protocols, which stalls experimentation. Bridging that gap is key.
AI: The Connector Between Human Intent and Robotic Action
Here’s where the momentum is real: artificial intelligence is becoming the missing link. Vision systems allow robots to “see” labware, plate layouts and context. Large Language Models (LLMs) can translate protocol changes or textual instructions into parameter adjustments on the fly.
Take Google DeepMind’s Gemini Robotics / Gemini Robotics-ER models, launched in 2025. They fuse vision, language, and action in a cohesive architecture, enabling robots to reason about new tasks rather than rely on rigid scripts. That is precisely the kind of intelligence we need in lab contexts.
Likewise, the market for AI-infused robotics is exploding. In 2025, the AI in robotics market is estimated to be $23.01 billion, jumping from $17.89 billion in 2024 (CAGR 28.6%). And the intelligent robotics (robot + AI) market is projected to grow from $13.99 billion in 2025 to over $50 billion by 2030 (CAGR 29.2%).
This convergence is the key: robots with built-in adaptability, real-time reprogramming and intent alignment.
Market Trends
The global lab automation market is estimated at $8.36 billion in 2025, growing to $14.78 billion by 2034. Some alternate analyses peg total lab automation at $6.65 billion in 2025 (CAGR ~6.82%) In biotech specifically, robotics in drug discovery is a hotspot. Adoption is accelerating for sample handling, HTS workflows, and automated screening.
In addition, roughly 50% of the life sciences workforce is hands-on, with ~65% of their time is in the lab. In Boston alone, that’s 20,000 lab workers, generating over 25 million lab-hours per year.
These numbers highlight an urgent reality: the gap between what labs need and what traditional robotics deliver has never been more stark.
Timing & Imperative
The U.S. life sciences workforce is over 2 million strong. But inefficiency is rampant: many bench protocols remain manual. At the same time, high turnover, labor shortages, and cost pressures are mounting.
As automation and intelligence technologies mature, the risk for labs is falling behind. In 2025, robots are no longer a futuristic luxury. They are becoming essential infrastructure in any lab serious about throughput, reproducibility and scale.
The Opportunity: Amplification, Not Replacement
Imagine a lab environment where a scientist writes a protocol in natural language; the robot interprets it, adjusts volumes, handles labware, error-checks, and integrates with LIMS/ELN systems. The scientist doesn’t type code or debug motion paths. They iterate hypotheses.
That’s not sci-fi. With our AI-driven lab robots, that hidden gap begins to close. Scientists can focus on discovery, not execution; insight, not implementation.
The revolution in biotech won’t happen on the factory floor. It will happen in the labs — where every scientist is empowered to run experiments faster, safer and smarter.
Chase Olle is the founder of Robot on Rails.